Role of nonhomologous end-joining in oral cancer and personalized pharmacogenomics

Da Tian Bau, Cheng Chieh Lin, Chang Fang Chiu, Ming Hsui Tsai*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Recent years have witnessed the incidence of cancer rise worldwide, with no end to the war against it in sight. It is believed that cancer emanates from a series of genetic alterations leading to the progressive disorder of the normal mechanisms that control cell proliferation, differentiation, death, and/or genomic stability. With our genome under constant exogenous and endogenous assault, cellular capacity to maintain genomic stability by means of various DNA repair mechanisms looms vital to preventing tumor initiation and progression. In the same vein, the relative role of DNA repair as biomarker for prognosis, predicator of drug and therapy response, or indeed as target for novel gene therapy, has been recently patented and is very promising. This paper summarizes studies probing association among nonhomologous end-joining genes XRCC4, XRCC5, and XRCC6 vis-à-vis oral cancer susceptibility, then discusses their role in carcinogenesis and personalized pharmacogenomics.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalBioMedicine (Netherlands)
Issue number1
StatePublished - 03 2012
Externally publishedYes


  • Carcinogenesis
  • Oral cancer
  • Polymorphism
  • XRCC4
  • XRCC5
  • XRCC6


Dive into the research topics of 'Role of nonhomologous end-joining in oral cancer and personalized pharmacogenomics'. Together they form a unique fingerprint.

Cite this